Inferior PFS in refractory/relapsed CLL treated with venetoclax has been associated with Tumor Protein 53 (TP53) dysfunction, bulky adenopathy, Notch1 mutations, prior B-Cell Receptor (BCR) therapy failure, and complex karyotype (8, 9). The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.